440 Result(s)
-
Article
Open AccessParacetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses
Although paracetamol (acetaminophen) combined with other analgesics can reduce pain intensity in some pain conditions, its effectiveness in managing low back pain and osteoarthritis is unclear. This systematic...
-
Article
Open AccessEffects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease
ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation being studied in a phase 2 trial in APOE4 carriers with early Alzheimer’s disease (AD) to ev...
-
Article
Open AccessAnalysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model
ALZ-801/valiltramiprosate is an oral, small-molecule inhibitor of beta-amyloid (Aβ) aggregation and oligomer formation in late-stage development as a disease-modifying therapy for early Alzheimer’s disease (AD...
-
Article
Open AccessBotulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews
Temporomandibular disorders (TMDs) encompass several conditions that cause pain and impair function of the masticatory muscles (M-TMDs) and temporomandibular joints. There is a large interest among clinicians ...
-
Article
Open AccessCorrection: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
-
Article
Open AccessTherapeutic Potential of Lipoprotein(a) Inhibitors
Increasing evidence has implicated lipoprotein(a) [Lp(a)] in the causality of atherosclerosis and calcific aortic stenosis. This has stimulated immense interest in develo** novel approaches to integrating Lp...
-
Article
Open AccessAnti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
Monoclonal antibodies targeting interleukin (IL)-5 pathways have revolutionized the treatment expectations for eosinophilic-associated conditions, particularly in patients with respiratory involvement. Mepoliz...
-
Article
Open AccessTargeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned
The development of new medicines for systemic lupus erythematosus (SLE) has not addressed unmet clinical need, with only three drugs receiving regulatory approval for SLE in the last 60 years, one of which was...
-
Article
Open AccessCorrection: Vonoprazan: A Review in Helicobacter pylori Infection
-
Article
Open AccessCorrection: Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain
-
Article
Open AccessRuxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Topical ruxolitinib 1.5% cream (Opzelura®), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in several countries for use in patients aged ≥ 12 years with non-segmental vitiligo. In the ident...
-
Article
Open AccessDrug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently used outcome to assess drug performance in practice. An ove...
-
Article
Open AccessSirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders
The sirtuin family is a heterogeneous group of proteins that play a critical role in many cellular activities. Several degenerative diseases have recently been linked to aberrant sirtuin expression and activit...
-
Article
Open AccessRecent United States Developments in the Pharmacological Treatment of Dry Eye Disease
Dry eye disease (DED) can arise from a variety of factors, including inflammation, meibomian gland dysfunction (MGD), and neurosensory abnormalities. Individuals with DED may exhibit a range of clinical signs,...
-
Article
Open AccessCorrection: Eplontersen: First Approval
-
Article
Open AccessEplontersen: First Approval
Eplontersen (Wainua™) is a ligand-conjugated antisense oligonucleotide directed to TTR, which is being developed by Ionis Pharmaceuticals and AstraZeneca for the treatment of TTR-mediated amyloidosis (ATTR). Eplo...
-
Article
Open AccessThe Pharmacological Landscape for Fatty Change of the Pancreas
The quest for medications to reduce intra-pancreatic fat deposition is now quarter a century old. While no specific medication has been approved for the treatment of fatty change of the pancreas, drug repurpos...
-
Article
Open AccessRelugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree® (USA); Ryeqo® (EU)] (hereafter referred to as relugolix combination therapy) has been approve...
-
Article
Open AccessTamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
Tamoxifen, a cornerstone in the adjuvant treatment of estrogen receptor-positive breast cancer, significantly reduces breast cancer recurrence and breast cancer mortality; however, its standard adjuvant dose o...
-
Article
Open AccessCorrection: Zilucoplan: First Approval
